Search results
Results from the WOW.Com Content Network
Protein-bound paclitaxel was developed by VivoRx which became Abraxis BioScience as the first in its class of drugs to use the nanoparticle albumin bound (nab) technology platform. [14] In 2010, Abraxis was acquired by Celgene, which now markets Abraxane. [15] Total revenue from the sales of Abraxane for 2009 were $314.5 million. [16]
Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from ...
Patrick Soon-Shiong (born July 29, 1952) is a South African and American businessman, investor, medical researcher, and transplant surgeon. He is the inventor of the drug Abraxane, which is used for lung, breast, and pancreatic cancer.
FDA Approves ABRAXANE ® for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Approval Based on Significantly Improved Overall Response Rates in all Patients Regardless of Histology ...
Celgene (NAS: CELG) is on a roll, scoring another win with its cancer drug Abraxane. The company announced FDA approval of Abraxane for first-line treatment of non-small cell lung cancer. This ...
ABRAXANE ® Phase III Study of Patients with Metastatic Pancreatic Cancer Published in New England Journal of Medicine BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly ...
Under this new name, seventy-four trials were undertaken to test Abraxane against various cancer targets. [8] The drug, which was approved by the FDA in 2005, was the subject of a litigation (Elan Pharma v. Abraxis BioScience) for patent infringement. [9] In 2008, Abraxis was ordered to pay $55.2 million to Elan. [9]
Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE ® sNDA in Advanced Pancreatic Cancer European Medicines Agency Accepts Regulatory Submission of Type II Variation for ABRAXANE for ...